IDXX - アイデックス・ラボラトリ―ズ （IDEXX Laboratories Inc.）

IDEXX Laboratories delivered solid and consistent results that rival the Googles, Metas, and Microsofts out there. Click here for more on IDXX.

Baron Funds, an investment management company, released its “Baron Asset Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. The fund increased by 12.21% in the fourth quarter, outperforming the Russell Midcap Growth Index which returned 6.90%. Stock selection and underexposure to stocks with high measures of Residual Volatility and […]

IDEXX Laboratories'' share price has increased over 55% since last October. See why I rate IDXX stock as a hold.

In December 2021, IDEXX Laboratories, Inc. (US) acquired Reference Laboratories (Finland) to expanded the company''s international reference laboratory presence. Northbrook, IL 60062 -- ( SBWIRE ) -- 02/08/2023 -- Legionella Testing Market is projected to grow from USD 296 million in 2022 to USD 439 million by 2027, at a CAGR of 8.2% from 2022 to 2027, according to a new report by MarketsandMarkets™. ,as businesses around the world look to protect their employees, customers and other visitors. Legionella testing is becoming an increasingly important part of many businesses'' safety and health protocols. As awareness of Legionella bacteria and the threat it poses to the health of building occupants grows, so does the demand for testing to ensure that Legionella levels in water systems remain low. In this blog post, we''ll take a look at the current state of the Legionella testing market, the key drivers of its growth and the challenges it faces. We''ll also look at the different types of Legionella tests available, the benefits they offer, and the importance of conducting regular testing.

IDEXX Laboratories (NASDAQ: IDXX ) has outperformed the market over the past 15 years by 13.26% on an annualized basis producing an average annual return of 20.86%. Currently, IDEXX Laboratories has a market capitalization of $40.54 billion. Buying $100 In IDXX: If … Full story available on Benzinga.com

Major players in the veterinary pain management market are CH Boehringer Sohn AG & Co KG, Zoetis Inc, Merck & Co Inc, Elanco Animal Health Incorporated, Ceva Santé Animale, Vetoquinol SA, Norbrook Laboratories Inc, Dechra Pharmaceuticals PLC, Chanelle Pharma, IDEXX Laboratories Inc, Assisi Animal Health, Bayer AG, Eli Lilly and Company, Novartis AG, and The International Veterinary Academy of Pain Management. Major players in the veterinary pain management market are CH Boehringer Sohn AG & Co KG, Zoetis Inc, Merck & Co Inc, Elanco Animal Health Incorporated, Ceva Santé Animale, Vetoquinol SA, Norbrook Laboratories Inc, Dechra Pharmaceuticals PLC, Chanelle Pharma, IDEXX Laboratories Inc, Assisi Animal Health, Bayer AG, Eli Lilly and Company, Novartis AG, and The International Veterinary Academy of Pain Management.

Major players in the veterinary reference laboratory market are IDEXX Laboratories Inc. , VCA Animal Hospitals, GD Animal Health, Boehringer Ingelheim, Zoetis Inc. , Neogen Corporation, Laboklin GmbH & Co. Major players in the veterinary reference laboratory market are IDEXX Laboratories Inc. , VCA Animal Hospitals, GD Animal Health, Boehringer Ingelheim, Zoetis Inc. , Neogen Corporation, Laboklin GmbH & Co.

Avian flu outbreak has so far claimed the lives of 50.54M birds in the U.S. this year, making it the nation''s worst on record, according to data from the U.S. Department of Agriculture

This 137% growth for IDXX stock since late 2018 can primarily be attributed to 1 the company''s P/S ratio rising 53% to 11.1x trailing revenues, from 7.3x in 2018, 2.

Jonathan Jay Mazelsky , President & CEO at IDEXX Laboratories (NASDAQ: IDXX ), reported a large insider sell on November 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Mazelsky sold 13,230 shares of IDEXX Laboratories . The total transaction amounted to $5,060,319. IDEXX Laboratories shares are trading up 6.32% at $403.87 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily … Full story available on Benzinga.com

Avian flu outbreak has so far claimed the lives of 50.54M birds in the U.S. this year, making it the nation''s worst on record, according to data from the U.S. Department of Agriculture

This 137% growth for IDXX stock since late 2018 can primarily be attributed to 1 the company''s P/S ratio rising 53% to 11.1x trailing revenues, from 7.3x in 2018, 2.

Jonathan Jay Mazelsky , President & CEO at IDEXX Laboratories (NASDAQ: IDXX ), reported a large insider sell on November 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Mazelsky sold 13,230 shares of IDEXX Laboratories . The total transaction amounted to $5,060,319. IDEXX Laboratories shares are trading up 6.32% at $403.87 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily … Full story available on Benzinga.com

At closing time on the New York Stock Exchange, the Dow Jones was down 0.24%, the S&P 500 was down 0.41% and the NASDAQ Composite was down 0.89%. The leaders among Dow Jones index components in today''s trading were shares of JPMorgan Chase & Co. which gained 2.28p (1.81%) to close at 128.16. Nike Inc rose 1.09 pct (1.18%) to close at 93.77. Goldman Sachs Group Inc rose 3.94p (1.14%) to close at 348.45. The least gainers were shares of Apple Inc, which fell 2.69p (1.75%) to close the session at 150.65. Salesforce Inc shares rose 2.79p (1.72%) to close at 159.80, while Microsoft Corporation dropped 3.96p (1.71%) to close at 228.17. The top gainers among S&P 500 index components in today''s trading were ABIOMED Inc which gained 49.88% to 377.82, IDEXX Laboratories Inc which gained 9.80% to close at 394.93, and Hologic Inc which gained 9.34% to end the session at 74.13. Catalent Inc shares were the fallers, down 24.62% to close at 49.55. Shares of Zebra Technologies Corporation lost 15.86% and ended the session at 238.30.

IDEXX Laboratories, Inc. (NASDAQ:NASDAQ:IDXX) Q3 2022 Earnings Conference Call November 1, 2022, 08:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - CEO Conference Call…